Rubius Therapeutics, Inc.
DelistedCIK 1709401fmd_09930KR5NNY88F4FH6QYW1GMJAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Dec 31, 2022, 25 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Operating income
- (178)
- Net income
- (180)
- Free cash flow
- (155)
Latest quarter · Q4 FY2022
Millions- Total revenues
- 0
- Operating income
- (23)
- Net income
- (20)
- Free cash flow
- (33)
Bulls and bears
Loading
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
AI-written
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- n/m
- Revenue, 5 yearsFY2017 to FY2022
- n/m
- Net income, 5 yearsFY2017 to FY2022
- n/m
Rubius Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 10-K 2023-02-27 · proof | |
| Operating income | -$178.4 million | -$194.6 million | 10-K 2023-02-27 · proof | |
| Net income | -$179.7 million | -$196.5 million | 10-K 2023-02-27 · proof | |
| Cash from operating activities | -$150.1 million | -$145.1 million | 10-K 2023-02-27 · proof | |
| Free cash flow | -$155.4 million | -$148.8 million | 10-K 2023-02-27 · proof | |
| Total assets | $23.1 million | $318 million | -92.7% | 10-K 2023-02-27 · proof |
| Total liabilities | $7.9 million | $139.2 million | -94.3% | 10-K 2023-02-27 · proof |
| Cash and cash equivalents | $14.9 million | $225.8 million | -93.4% | 10-K 2023-02-27 · proof |
| Total debt | $0 | $76.2 million | -100% | 10-K 2023-02-27 · proof |
- What was Rubius Therapeutics, Inc.'s revenue in fiscal 2022?
- Rubius Therapeutics, Inc. reported revenue of $0 for fiscal 2022 (the year ended Dec 31, 2022), against $0 the year before. Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What was Rubius Therapeutics, Inc.'s operating income in fiscal 2022?
- Rubius Therapeutics, Inc. reported operating income of -$178.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$194.6 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What was Rubius Therapeutics, Inc.'s net income in fiscal 2022?
- Rubius Therapeutics, Inc. reported net income of -$179.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$196.5 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What was Rubius Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
- Rubius Therapeutics, Inc. reported cash from operating activities of -$150.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -$145.1 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What was Rubius Therapeutics, Inc.'s free cash flow in fiscal 2022?
- Rubius Therapeutics, Inc. reported free cash flow of -$155.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$148.8 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What are Rubius Therapeutics, Inc.'s total assets?
- As of Dec 31, 2022, Rubius Therapeutics, Inc. reported total assets of $23.1 million, against $318 million a year earlier (-92.7%). Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What are Rubius Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2022, Rubius Therapeutics, Inc. reported total liabilities of $7.9 million, against $139.2 million a year earlier (-94.3%). Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What are Rubius Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Rubius Therapeutics, Inc. reported cash and cash equivalents of $14.9 million, against $225.8 million a year earlier (-93.4%). Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
- What is Rubius Therapeutics, Inc.'s total debt?
- As of Dec 31, 2022, Rubius Therapeutics, Inc. reported total debt of $0, against $76.2 million a year earlier (-100%). Source: the 10-K filed with the SEC on Feb 27, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1709401&period_type=annual&limit=5"Information only, not investment advice.